Table 2.
Incremental costs per patient, Incremental QALYs per patient, ICERs, and the probability that SoC + Sativex® is the dominant treatment option for the three scenarios
| Time horizon | Incremental costs | Incremental QALYs | ICER | Dominance probability (%) | |||
|---|---|---|---|---|---|---|---|
| Base case | |||||||
| 1 year | € 759 | [- € 1,889, € 2,434] | 0.034 | [0.01, 0.06] | 22,187 | [-€63,201, €116,936] | 29 |
| 2 years | - € 746 | [- € 7,011, € 2,866] | 0.072 | [0.02, 0.14] | − 10,387 | [-€106,280, € 75,901] | 67 |
| 3 years | - € 2,610 | [- € 11,304, € 2,512] | 0.103 | [0.03, 0.20] | − 25,417 | [-€ 144,701, € 44,239] | 82 |
| 4 years | - € 4,440 | [- € 15,798, € 1,939] | 0.127 | [0.03, 0.24] | − 35,051 | [-€ 145,330, € 24,614] | 89 |
| 5 years | - € 6,068 | [- € 18,833, € 1,442] | 0.145 | [0.04, 0.28] | − 41,942 | [-€ 141,444, € 19,045] | 94 |
| Scenario 1 | |||||||
| 1 year | € 1,367 | [- € 1,297, € 3,149] | 0.018 | [0.00, 0.04] | 75,658 | [-€ 514,022, € 874,758] | 13 |
| 2 years | € 940 | [- € 4,628, € 4,494] | 0.039 | [- 0.01, 0.09] | 24,300 | [-€ 381,126, € 497,073] | 34 |
| 3 years | € 518 | [- € 7,023, € 5,728] | 0.052 | [- 0.02, 0.13] | 9,976 | [-€ 581,595, € 637,440] | 39 |
| 4 years | € 402 | [- € 10,046, € 6,992] | 0.058 | [- 0.04, 0.16] | 6,979 | [-€ 536,674, € 762,140] | 46 |
| 5 years | € 688 | [- € 11,394, € 8,589] | 0.057 | [- 0.05, 0.17] | 12,178 | [-€ 704,778, €834,316] | 43 |
| Scenario 2 | |||||||
| 1 year | € 1,156 | [- € 1,399, € 2,527] | 0.029 | [0.01, 0.05] | 40,208 | [-€ 45,976, € 138,371] | 18 |
| 2 years | € 1,001 | [- € 3,520, € 3,618] | 0.051 | [0.02, 0.09] | 19,697 | [-€ 72,420, € 107,989] | 33 |
| 3 years | € 764 | [- € 6,465, € 4,551] | 0.055 | [0.03, 0.11] | 11,788 | [-€ 80,727, € 93,624] | 42 |
| 4 years | € 510 | [- € 5,375, € 5,293] | 0.074 | [0.03, 0.13] | 6,921 | [-€ 106,279, € 85,046] | 46 |
| 5 years | € 270 | [- € 7,175, € 4,855] | 0.079 | [0.03, 0.14] | 3,401 | [-€ 102,361, €88,701] | 49 |
Numbers between brackets indicate the 95% confidence intervals